Table 2. Results of survival analyses by individual study.
| Overall Survival | Event Free Survival | |||||||
| Study | Univariate | Multivariate | Univariate | Multivariate | ||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| NSCLC No Chemotherapy | ||||||||
| Simon et al. [37] | 0.34 | 0.14–0.83 | 0.24 | 0.08–0.77 | — | — | — | — |
| Olaussen et al. [36] (B) | — | — | 0.66 | 0.49–0.90 | — | — | — | — |
| Zeng et al. [34] | 0.54* | 0.34–0.86* | — | — | 0.64* | 0.38–1.10* | — | — |
| Rosell et al. [30] | 0.96* | 0.53–1.74* | — | — | 0.96* | 0.51–1.79* | — | — |
| Lee et al. [29] | 0.61* | 0.38–0.99* | 0.60 | 0.36–1.00 | — | — | — | — |
| Okuda et al. [28] (B) | 1.68* | 0.69–4.06* | 1.62 | 0.71–3.70 | — | — | — | — |
| Bartolucci et al. [24] | 2.07* | 0.94–4.54* | 1.17 | 0.62–2.21 | 1.71* | 0.78–3.76* | 1.15 | 0.56–2.37 |
| NSCLC Platinum Treated | ||||||||
| Lord et al. [39] | 2.39* | 1.24–4.59* | 3.13 | 1.41–7.14 | — | — | — | — |
| Rosell et al. [38] (A) | 0.59* | 0.26–1.30* | — | — | 0.92* | 0.45–1.91* | — | — |
| Olaussen et al. [36] (A) | — | — | 1.16 | 0.86–1.56 | — | — | — | — |
| Ceppi et al. [35] | 2.28* | 1.32–3.94* | — | — | — | — | — | — |
| Booton et al. [31] | 0.91* | 0.45–1.85* | 0.96 | 0.92–1.00 | — | — | — | — |
| Azuma et al. [33] | 2.99* | 1.60–5.59* | 1.65 | 1.21–2.28 | 2.22* | 1.24–3.97* | 1.37 | 1.07–1.76 |
| Fujii et al. [32] (A) | 1.48* | 0.45–4.82* | — | — | 1.65* | 0.48–5.71* | — | — |
| Fujii et al. [32] (B) | 1.85* | 0.30–11.65* | — | — | 0.62* | 0.15–2.65* | — | — |
| Okuda et al. [28] (A) | 2.43* | 1.28–4.61* | 2.31 | 1.24–4.31 | — | — | — | — |
| Hwang et al. [21] | 2.14* | 1.17–3.93* | 2.07 | 1.03–4.17 | 1.77* | 0.97–3.23* | 1.57 | 0.83–2.98 |
| Lee et al. [41] | 1.79* | 0.99–3.25* | 3.16 | 1.54–6.46 | — | — | — | — |
| Azuma et al. [22] | 1.73* | 0.74–4.09* | 2.41 | 0.86–6.76 | 2.79* | 1.29–6.03* | 3.97 | 1.41–11.23 |
| Ota et al. [26] | 1.46* | 1.04–2.05* | 1.33 | 0.93–1.92 | 0.69* | 0.47–1.02* | 1.22 | 0.79–1.85 |
| Wang et al. [42] | — | — | 1.72 | 1.16–2.53 | — | — | — | — |
| Holm et al. [43] | — | — | 1.24 | 1.01–1.51 | — | — | — | — |
| Jeong et al. [44] | 0.64* | 0.32–1.28* | — | — | — | — | — | — |
| NSCLC Non-Platinum Treated | ||||||||
| Rosell et al. [38] (B) | 0.77* | 0.34–1.74* | — | — | 1.08* | 0.52–2.26* | — | — |
| SCLC | ||||||||
| Ceppi et al. [27] (All patients) | 1.46* | 0.94–2.26* | — | — | — | — | — | — |
| Ceppi et al. [27] (B; LS) | 2.19* | 1.19–4.04* | 2.06 | 1.18–4.38 | — | — | — | — |
| Lee et al. [23] (A; ES) | 0.82* | 0.37–1.79* | 1.07 | 0.46–2.49 | — | — | — | — |
| Lee et al. [23] (B; LS) | 3.66* | 1.26–10.60* | 2.80 | 1.02–2.39 | — | — | — | — |
| Kim et al. [40] | 0.90* | 0.61–1.35* | — | — | — | — | — | — |
HRs and associated 95% CIs are given as quoted unless stated otherwise, (—) indicates not assessed;
*estimated result from data presented in paper using methods of Palmer et al. (REF);
HR, hazard ratio; CI, confidence interval; LS, limited stage; ES, extensive stage.